In Vivo Generation of CAR-T Cells: Current Obstacles, Strategic Solutions, and Clinical Translation - PubMed
2 hours ago
- #clinical translation
- #in vivo generation
- #CAR-T therapy
- Chimeric antigen receptor T (CAR-T) cell therapy is a breakthrough for hematologic malignancies, but traditional ex vivo manufacturing is expensive, time-consuming, and not easily scalable.
- In vivo generation of CAR-T cells, where endogenous T cells are reprogrammed directly inside patients using engineered vectors, presents a simpler and more accessible option.
- Key challenges include inefficient systemic delivery, off-target transduction, balancing transfection efficiency with safety, and short-lived CAR expression.
- Innovative strategies like targeted vector systems, combinatorial T-cell recognition, tunable expression control, and methods to boost durability are being developed.
- Early-phase clinical trials confirm that inducing CAR-T cells in vivo is feasible, paving the way for future translation of this therapy.